1. In solid organ transplantation, cytomegalovirus (CMV — a herpesvirus that establishes lifelong latency and reactivates under immune suppression) risk is stratified by the CMV antibody status of the organ donor and the recipient. Which donor/recipient serostatus combination carries the HIGHEST risk of CMV infection and end-organ disease?
A) Donor-negative / Recipient-positive (D-/R+), because the recipient's latent virus reactivates against a naive graft
B) Donor-negative / Recipient-negative (D-/R-), because neither party has protective antibody
C) Donor-positive / Recipient-negative (D+/R-), because the recipient lacks pre-existing CMV-specific immunity and receives a graft containing latent virus
D) Donor-positive / Recipient-positive (D+/R+), because two viral strains are present simultaneously
E) The combinations carry equal risk because immunosuppression is the only determinant
ANSWER: C
Rationale:
The donor/recipient serostatus matrix predicts CMV risk because it captures both the presence of latent virus in the graft and the recipient's pre-existing CMV-specific cellular memory. Option C is correct: in D+/R-, the seronegative recipient has no CMV-specific memory T cells and receives an organ carrying latently infected donor cells that reactivate under immunosuppression; without prophylaxis, infection occurs in 50-80% of these patients and 20-30% develop end-organ disease.
Option A: Option A is incorrect: R+ patients (any donor) carry an intermediate 10-30% reactivation risk from their own latent virus, lower than D+/R- because they possess some CMV-specific memory.
Option B: Option B is incorrect: D-/R- carries the LOWEST risk because neither latent reactivation nor a virus-bearing graft is present; risk is limited to primary acquisition from blood products or community exposure.
Option D: Option D is incorrect: D+/R+ recipients have pre-existing immunity that substantially mitigates risk, and "two strains" does not define the highest-risk category.
Option E: Option E is incorrect: while immunosuppression amplifies risk, serostatus is an independent and primary determinant that guides prophylaxis decisions.
2. Letermovir is used to prevent CMV reactivation in hematopoietic stem cell transplant recipients. Unlike older anti-CMV drugs that block the viral DNA polymerase, letermovir acts by a distinct mechanism. What is letermovir's mechanism of action?
A) Inhibition of the CMV terminase complex, the enzyme machinery that packages newly made viral DNA into the viral capsid
B) Inhibition of the viral DNA polymerase after activation by the UL97 phosphotransferase
C) Direct inhibition of the viral DNA polymerase without requiring activation
D) Inhibition of the viral protease that cleaves structural polyproteins
E) Blockade of viral entry by preventing fusion with the host cell membrane
ANSWER: A
Rationale:
Understanding where a drug acts in the viral replication cycle explains both its spectrum and its side-effect profile. Option A is correct: letermovir inhibits the CMV terminase complex (encoded by UL56, UL89, and UL51), which cleaves and packages concatemeric viral DNA into procapsids; because this enzyme has no human counterpart and is unrelated to DNA polymerase, letermovir is highly CMV-specific and free of myelosuppression.
Option B: Option B is incorrect: that describes ganciclovir, which depends on UL97 phosphorylation and then inhibits the polymerase.
Option C: Option C is incorrect: direct, activation-independent polymerase inhibition describes foscarnet.
Option D: Option D is incorrect: no anti-CMV agent in current use targets a viral protease in this manner.
Option E: Option E is incorrect: letermovir does not act at the entry/fusion step. Letermovir is also notable for having no activity against herpes simplex virus or varicella-zoster virus.
3. Ganciclovir (and its oral prodrug valganciclovir) is a first-line drug for CMV disease. Before it can inhibit viral DNA synthesis, ganciclovir must be converted to its active triphosphate form. The first and rate-limiting step of this activation is performed by a CMV-encoded enzyme. Which enzyme carries out that first activating step?
A) Host-cell thymidine kinase, which phosphorylates the drug independently of the virus
B) The CMV terminase complex, which cleaves viral DNA concatemers
C) The CMV DNA polymerase encoded by the UL54 gene
D) The CMV UL97 phosphotransferase (protein kinase), which adds the first phosphate to ganciclovir
E) A host plasma esterase that hydrolyzes the prodrug to the active form
ANSWER: D
Rationale:
A drug that requires viral activation is only active where the virus is replicating, and mutations in the activating enzyme are a common route to resistance. Option D is correct: ganciclovir is first monophosphorylated by the CMV UL97 phosphotransferase; host kinases then add the second and third phosphates, and ganciclovir triphosphate inhibits the viral DNA polymerase. Because UL97 is virus-specific, the drug concentrates in infected cells.
Option A: Option A is incorrect: host thymidine kinase activates acyclovir-type drugs against HSV/VZV, not ganciclovir against CMV (CMV lacks the relevant thymidine kinase).
Option B: Option B is incorrect: the terminase complex is the target of letermovir, not an activating enzyme.
Option C: Option C is incorrect: UL54 (DNA polymerase) is the eventual target of the activated drug, not the activator.
Option E: Option E is incorrect: valganciclovir is hydrolyzed to ganciclovir by intestinal/hepatic esterases, but that yields the parent nucleoside, not the active triphosphate; the rate-limiting activating step is UL97 phosphorylation. This is why UL97 mutations are the most common cause of ganciclovir resistance.
4. Cidofovir is active against a broad range of double-stranded DNA viruses, including CMV strains that have become resistant to ganciclovir because of mutations in the viral activating kinase. What feature of cidofovir explains why such ganciclovir-resistant strains often remain susceptible to it?
A) Cidofovir inhibits the viral terminase rather than the DNA polymerase
B) Cidofovir is a nucleotide analogue already bearing a phosphonate group, so it is activated by host-cell kinases and does not require any viral enzyme for activation
C) Cidofovir is activated specifically by the CMV UL97 phosphotransferase, but at a different binding site
D) Cidofovir blocks viral entry and therefore bypasses the need for intracellular activation
E) Cidofovir is a protease inhibitor and acts downstream of DNA replication
ANSWER: B
Rationale:
Whether a drug depends on a viral enzyme for activation predicts its cross-resistance pattern. Option B is correct: cidofovir is an acyclic nucleoside phosphonate — it already carries a phosphonate group that mimics the first phosphate, so only host-cell kinases are needed to reach the active diphosphate. Because no viral kinase is required, UL97 mutations that abolish ganciclovir activation do not affect cidofovir, which then competitively inhibits the viral DNA polymerase.
Option A: Option A is incorrect: cidofovir targets the DNA polymerase, not the terminase (that is letermovir).
Option C: Option C is incorrect: the whole point is that cidofovir does NOT depend on UL97; if it did, UL97-mutant strains would be cross-resistant.
Option D: Option D is incorrect: cidofovir acts intracellularly on DNA synthesis, not at viral entry.
Option E: Option E is incorrect: cidofovir is not a protease inhibitor. This activation-independent mechanism also underlies cidofovir's broad activity against adenovirus, BK polyomavirus, and orthopoxviruses.
5. Foscarnet is used for CMV disease when ganciclovir cannot be used, including ganciclovir-resistant infection. Among the anti-CMV agents, foscarnet is unusual in requiring no intracellular activation at all. How does foscarnet inhibit viral replication?
A) It must be triphosphorylated by viral and host kinases before it can act
B) It inhibits the CMV terminase complex and prevents DNA packaging
C) It is a nucleoside analogue that is incorporated into the growing DNA chain and terminates it
D) It blocks the UL97 phosphotransferase and prevents activation of other antivirals
E) It is a pyrophosphate analogue that directly binds the pyrophosphate-binding site of the viral DNA polymerase, blocking it without any activation step
ANSWER: E
Rationale:
Knowing that foscarnet needs no activation explains why it works against strains resistant to drugs that DO require activation. Option E is correct: foscarnet is an inorganic pyrophosphate analogue that binds directly to the pyrophosphate-binding region of the viral DNA polymerase, preventing cleavage of pyrophosphate from incoming nucleotides and halting chain elongation — with no phosphorylation required. Because it acts directly on the polymerase, UL97-mediated (kinase) resistance does not affect it.
Option A: Option A is incorrect: foscarnet is specifically NOT phosphorylated; that describes nucleoside analogues like ganciclovir.
Option B: Option B is incorrect: terminase inhibition is letermovir's mechanism.
Option C: Option C is incorrect: foscarnet is not incorporated into DNA; it is not a nucleoside analogue.
Option D: Option D is incorrect: foscarnet does not target UL97; it bypasses the activation problem entirely. Foscarnet's principal toxicities are nephrotoxicity and electrolyte disturbances (hypocalcemia, hypomagnesemia, hypokalemia).
6. Two strategies are used to prevent CMV end-organ disease after transplantation: universal prophylaxis and pre-emptive therapy. A transplant program performs weekly quantitative CMV PCR (a blood test measuring viral copies) on at-risk patients and starts antiviral treatment only when the viral load crosses a defined threshold, before any symptoms appear. Which strategy does this describe?
A) Pre-emptive therapy, because antiviral treatment is triggered by surveillance evidence of replication rather than given to everyone
B) Universal prophylaxis, because all at-risk patients are monitored
C) Secondary prophylaxis, because treatment follows established end-organ disease
D) Suppressive therapy, because the drug is continued indefinitely after a clinical episode
E) Salvage therapy, because it is reserved for drug-resistant infection
ANSWER: A
Rationale:
Distinguishing these strategies matters because each has different toxicity and breakthrough trade-offs. Option A is correct: pre-emptive therapy uses scheduled viral-load monitoring and treats only when a threshold is crossed, sparing antiviral exposure in patients who never reach it — at the cost of requiring reliable lab infrastructure and adherence to surveillance.
Option B: Option B is incorrect: universal prophylaxis gives antiviral drug to ALL high-risk patients for a fixed period regardless of viral load, so the presence of monitoring alone does not define a prophylaxis strategy.
Option C: Option C is incorrect: secondary prophylaxis prevents relapse AFTER treated disease, not before first replication.
Option D: Option D is incorrect: suppressive therapy implies ongoing treatment following a clinical episode.
Option E: Option E is incorrect: salvage therapy refers to treatment after failure of first-line agents, typically in resistant disease. A known trade-off of universal prophylaxis is late-onset CMV disease emerging after the drug is stopped.
7. A hematopoietic stem cell transplant recipient is CMV-seropositive and already at risk for prolonged neutropenia (low white-cell count) after the conditioning chemotherapy. The team wants CMV prophylaxis that will not worsen the bone-marrow suppression. Which property makes letermovir particularly well suited to this setting?
A) Letermovir also treats herpes simplex and varicella-zoster, broadening coverage
B) Letermovir is renally cleared and therefore safe regardless of marrow status
C) Letermovir has no myelosuppressive effect, because its target (the viral terminase) has no human counterpart and it does not act on DNA polymerase
D) Letermovir reverses chemotherapy-induced neutropenia by stimulating granulocyte production
E) Letermovir is dosed once weekly, which minimizes cumulative marrow toxicity
ANSWER: C
Rationale:
Choosing among agents in a cytopenic patient hinges on which drugs add to marrow toxicity. Option C is correct: because letermovir inhibits the CMV-specific terminase complex — an enzyme with no mammalian homologue — and does not interfere with host DNA synthesis the way ganciclovir does, it carries no myelosuppressive burden, a decisive advantage in HSCT recipients already prone to neutropenia.
Option A: Option A is incorrect and clinically important: letermovir has NO activity against HSV or VZV, so separate coverage is needed if those are a concern.
Option B: Option B is incorrect: route of elimination does not determine marrow safety, and the premise is wrong as the reason.
Option D: Option D is incorrect: letermovir does not stimulate granulopoiesis (that describes G-CSF).
Option E: Option E is incorrect: letermovir is dosed once daily, and dosing frequency is not why it spares the marrow. Ganciclovir/valganciclovir, by contrast, are limited in HSCT precisely because of their myelosuppression.
8. Among the end-organ forms of CMV disease in allogeneic hematopoietic stem cell transplant recipients, which manifestation is the most feared because it carries the highest mortality (roughly 30-50%) even with antiviral therapy?
A) CMV retinitis, because it causes irreversible blindness
B) CMV colitis, because it produces severe diarrhea and dehydration
C) CMV esophagitis, because it prevents oral intake
D) CMV pneumonitis, because it produces progressive hypoxemic respiratory failure with mortality of roughly 30-50% despite treatment
E) CMV hepatitis, because it leads to fulminant liver failure
ANSWER: D
Rationale:
Recognizing the most lethal presentation drives aggressive, combination management. Option D is correct: CMV pneumonitis is the most feared CMV complication in allogeneic HSCT recipients, with mortality of about 30-50% despite IV ganciclovir; it is typically managed with ganciclovir PLUS intravenous immunoglobulin (IVIG) to add CMV-specific neutralizing antibody at the alveolar surface, together with reduction of immunosuppression where feasible.
Option A: Option A is incorrect: retinitis is sight-threatening but classically a problem of advanced HIV with very low CD4 counts and is far less lethal.
Option B: Option B is incorrect: CMV colitis is serious but not the highest-mortality form; it is diagnosed by colonoscopic biopsy.
Option C: Option C is incorrect: esophagitis causes odynophagia but is not the leading cause of CMV death in HSCT.
Option E: Option E is incorrect: CMV hepatitis occurs but rarely produces the mortality seen with pneumonitis. As with colitis and pneumonitis, blood CMV PCR can be falsely negative, so bronchoalveolar lavage is required for diagnosis.
9. A transplant recipient with profuse diarrhea undergoes colonoscopy with biopsy. The pathologist describes large infected cells containing prominent intranuclear inclusions surrounded by a clear halo — the classic "owl-eye" appearance. Which virus does this histologic finding identify?
A) Epstein-Barr virus
B) Cytomegalovirus
C) BK polyomavirus
D) Adenovirus
E) JC virus
ANSWER: B
Rationale:
Linking a hallmark histologic finding to the responsible virus is a core diagnostic skill, especially when blood tests can be negative. Option B is correct: the "owl-eye" intranuclear inclusion is the pathognomonic cytologic signature of CMV-infected cells, confirmed with CMV immunohistochemistry or in situ hybridization; tissue diagnosis is essential in CMV colitis because blood CMV PCR is frequently negative in disease confined to the gut.
Option A: Option A is incorrect: EBV-driven disease (PTLD) is identified by EBV-encoded RNA (EBER) in proliferating B cells, not owl-eye inclusions.
Option C: Option C is incorrect: BK polyomavirus produces "decoy cells" in urine and intranuclear inclusions in renal tubular cells, but the owl-eye descriptor specifically denotes CMV.
Option D: Option D is incorrect: adenovirus produces smudge-cell inclusions, not the haloed owl-eye.
Option E: Option E is incorrect: JC virus infects oligodendrocytes in the brain (PML) and is not diagnosed on colon biopsy. In an HSCT recipient, distinguishing CMV colitis from graft-versus-host disease is critical because the two require opposite treatments.
10. A neutropenic transplant recipient has several days of bloody diarrhea. Blood CMV PCR is negative. The clinical picture still strongly suggests tissue-invasive CMV disease. What does the negative blood test tell you, and what is the appropriate next step?
A) CMV is excluded; stop considering it and pursue other diagnoses only
B) The negative PCR proves the diarrhea is graft-versus-host disease; escalate corticosteroids
C) Repeat the blood PCR daily and withhold any further workup until it turns positive
D) Switch empirically to foscarnet, since a negative PCR indicates ganciclovir resistance
E) A negative blood PCR does not exclude tissue-invasive CMV; obtain colonoscopy with biopsy for histology and CMV staining
ANSWER: E
Rationale:
This question connects a laboratory limitation to a concrete diagnostic action. Option E is correct: in CMV colitis (and also pneumonitis and encephalitis) the virus can replicate locally without producing detectable viremia, so a negative blood PCR cannot rule out tissue-invasive disease; the appropriate step is tissue sampling — colonoscopy with biopsy showing owl-eye inclusions and confirmatory CMV immunostaining.
Option A: Option A is incorrect: excluding CMV on a negative blood test is the central error this question targets.
Option B: Option B is incorrect and dangerous: assuming GVHD and escalating steroids without tissue diagnosis can worsen untreated CMV, since the two diseases look alike but need opposite treatments.
Option C: Option C is incorrect: passively waiting for the blood test to convert delays diagnosis in a deteriorating patient.
Option D: Option D is incorrect: a negative blood PCR says nothing about drug resistance, and switching agents empirically is unjustified. In a deteriorating immunocompromised patient with a compatible picture, antiviral therapy should not be withheld solely while awaiting tissue results.
11. Post-transplant lymphoproliferative disorder (PTLD) is an EBV-driven proliferation of B cells that arises when transplant immunosuppression weakens the T-cell surveillance that normally controls EBV. Acyclovir and ganciclovir are largely ineffective for established PTLD. What is the mechanistic reason?
A) PTLD is driven by latently infected B cells that do not express the viral thymidine kinase needed to activate these drugs, because the drugs only target actively (lytically) replicating virus
B) PTLD cells overexpress the viral DNA polymerase, which the drugs cannot reach
C) The drugs are inactivated by host enzymes before reaching lymphoid tissue
D) PTLD is caused by CMV rather than EBV, so EBV-active drugs do not apply
E) The B cells pump the drug out via efflux transporters, producing resistance
ANSWER: A
Rationale:
This connects EBV's latency biology to why a whole drug class fails. Option A is correct: acyclovir and ganciclovir require phosphorylation by a virally encoded thymidine kinase (TK) that is expressed only during lytic replication; PTLD is driven by B cells in the latency program, which do not express TK, so the drugs are never activated and cannot act — the disease is immunological, not lytic.
Option B: Option B is incorrect: PTLD cells are not characterized by polymerase overexpression, and the limitation is activation, not access to the polymerase.
Option C: Option C is incorrect: host inactivation is not the reason; the failure is the absence of viral TK.
Option D: Option D is incorrect: PTLD is an EBV-driven process, not a CMV one.
Option E: Option E is incorrect: efflux-pump resistance is not the mechanism here. This is why effective therapy targets the B cells and the immune deficit — reducing immunosuppression and giving anti-CD20 antibody — rather than the viral polymerase.
12. Because antiviral drugs do not work for established PTLD, treatment targets the proliferating B cells themselves. The monoclonal antibody rituximab is a mainstay of therapy. What is rituximab's target, and why does that make it effective in EBV-positive PTLD?
A) It binds CD3 on T cells and restores antiviral surveillance
B) It neutralizes free EBV particles in the blood and prevents new B-cell infection
C) It binds CD20 on B cells and depletes them — eliminating the EBV-harboring cell population that drives PTLD
D) It inhibits the viral DNA polymerase within latently infected cells
E) It blocks the interleukin-6 receptor and suppresses B-cell growth signaling
ANSWER: C
Rationale:
This links the drug's molecular target to the cell population responsible for disease. Option C is correct: rituximab is an anti-CD20 chimeric monoclonal antibody; CD20 is expressed on B lymphocytes, which are the reservoir of EBV in PTLD, so depleting CD20+ cells removes the proliferating, virus-harboring population. Typical dosing is 375 mg/m^2 IV weekly for four doses, with response rates around 40-60%, higher when combined with reduction of immunosuppression.
Option A: Option A is incorrect: anti-CD3 (muromonab) targets T cells and is itself a risk factor for PTLD, not a treatment.
Option B: Option B is incorrect: rituximab does not work by neutralizing free virions; PTLD is driven by latently infected cells, not circulating virus.
Option D: Option D is incorrect: rituximab is an antibody against a surface protein, not a polymerase inhibitor.
Option E: Option E is incorrect: rituximab does not target the IL-6 receptor. Aggressive monomorphic PTLD resembling diffuse large B-cell lymphoma often requires rituximab combined with chemotherapy.
13. A solid organ transplant recipient is diagnosed with early, polymorphic EBV-positive PTLD. According to the standard management hierarchy, what is the FIRST intervention that should be applied whenever it is clinically feasible?
A) Begin R-CHOP combination chemotherapy immediately
B) Reduce immunosuppression to allow recovery of EBV-specific cytotoxic T-cell surveillance
C) Start high-dose IV ganciclovir
D) Administer four weekly doses of rituximab before any other change
E) Perform splenectomy to remove the bulk of proliferating B cells
ANSWER: B
Rationale:
Knowing the ordered hierarchy connects the underlying biology to the sequence of clinical action. Option B is correct: because PTLD arises from failed T-cell surveillance, the first step — when feasible — is reduction of immunosuppression (reducing or withdrawing calcineurin inhibitors and antimetabolites) to let EBV-specific cytotoxic T cells reconstitute; this alone produces responses in roughly 20-40% of early polymorphic PTLD.
Option A: Option A is incorrect: R-CHOP is reserved for aggressive monomorphic disease or failure of earlier steps, not the first move.
Option C: Option C is incorrect: antivirals do not treat established PTLD because latent B cells lack viral thymidine kinase.
Option D: Option D is incorrect: rituximab is the next step if reduction of immunosuppression is insufficient or disease progresses — it is added to, not placed before, the foundational step.
Option E: Option E is incorrect: splenectomy is not part of the standard hierarchy. The sequence is reduce immunosuppression, then rituximab, then chemotherapy for monomorphic disease.
14. A kidney transplant recipient develops rising plasma BK polyomavirus viral load and a creeping serum creatinine, and biopsy confirms BK polyomavirus nephropathy. There is no antiviral agent approved for BK virus. What is the cornerstone of management?
A) High-dose IV ganciclovir, which is virus-specific for BK
B) Lifelong valganciclovir suppression
C) Letermovir, repurposed for its terminase activity against BK
D) Reduction of immunosuppression to allow BK-specific cytotoxic T cells to control the virus
E) Immediate allograft nephrectomy
ANSWER: D
Rationale:
This connects the absence of an effective drug to the immunologic logic of treatment. Option D is correct: because no antiviral is approved or reliably effective for BK virus, the cornerstone of BK nephropathy management is reducing immunosuppression — lowering the calcineurin-inhibitor target and reducing or stopping the antimetabolite — which permits reconstitution of BK-specific cytotoxic T-lymphocyte control; this is guided by serial plasma BK PCR, ideally acting pre-emptively before nephropathy is established.
Option A: Option A is incorrect: ganciclovir is not active against BK polyomavirus.
Option B: Option B is incorrect: valganciclovir does not treat BK and would add toxicity without benefit.
Option C: Option C is incorrect: letermovir is CMV-specific (the CMV terminase) and has no role in BK disease.
Option E: Option E is incorrect: nephrectomy is not first-line; the aim is to salvage the graft by restoring immune control. Low-dose cidofovir or leflunomide are used only in refractory cases and on limited observational evidence.
15. Cidofovir is used for disseminated adenovirus disease in transplant recipients, but its major dose-limiting toxicity is damage to the kidney's proximal tubule. To reduce this nephrotoxicity, each infusion is given with a specific supportive protocol. What does that protocol consist of?
A) Loop diuretic plus potassium supplementation during the infusion
B) Allopurinol pretreatment to reduce uric acid load
C) N-acetylcysteine infusion before and after the dose
D) Empiric dose reduction of the calcineurin inhibitor on infusion days
E) Oral probenecid before and after the dose plus intravenous saline hydration, to reduce drug uptake into proximal tubular cells
ANSWER: E
Rationale:
This connects the site of toxicity to the rationale for the supportive regimen. Option E is correct: cidofovir is taken into proximal tubular cells by the organic anion transporter (OAT1), where it accumulates and causes injury; probenecid competitively blocks OAT1-mediated uptake, and saline hydration further limits tubular exposure, so the standard protocol is oral probenecid (before and after the infusion) plus pre-infusion IV normal saline. Renal function and proteinuria must be checked before each dose, and the drug is contraindicated below a defined creatinine-clearance threshold.
Option A: Option A is incorrect: loop diuretics are not the protective strategy and could worsen volume status.
Option B: Option B is incorrect: allopurinol targets urate, irrelevant to cidofovir tubular uptake.
Option C: Option C is incorrect: N-acetylcysteine is not the established cidofovir protocol.
Option D: Option D is incorrect: while CNI levels are monitored because cidofovir-induced renal impairment reduces their clearance, prophylactic CNI dose reduction is not the nephroprotective protocol for the infusion itself. Brincidofovir, a lipid conjugate, avoids OAT1 uptake and thereby the nephrotoxicity.
16. A patient on ganciclovir for CMV disease has a viral load that fails to fall after two weeks of adequate dosing. Genotypic testing shows a mutation in the UL97 gene (the CMV phosphotransferase) but a normal UL54 gene (the CMV DNA polymerase). Using what you know about how each anti-CMV drug is activated, which agent is the rational next choice?
A) Foscarnet, because it inhibits the DNA polymerase directly and needs no UL97-mediated activation
B) A higher dose of the same ganciclovir, because the resistance is only partial
C) Valganciclovir, because the oral prodrug bypasses the UL97 requirement
D) Letermovir, because terminase inhibition overcomes polymerase-level resistance
E) Acyclovir, because it is activated by a different viral kinase that remains functional
ANSWER: A
Rationale:
This bridges the activation mechanisms established earlier (Questions 3 and 5) to a resistance scenario. Option A is correct: a UL97 mutation impairs phosphorylation (activation) of ganciclovir, but foscarnet requires no activation — it binds the viral DNA polymerase directly — and because UL54 is intact, the polymerase remains susceptible; switching to foscarnet is the standard response to isolated UL97 resistance.
Option B: Option B is incorrect: escalating a drug the virus cannot activate does not restore efficacy.
Option C: Option C is incorrect: valganciclovir is simply oral ganciclovir and depends on the same UL97 activation, so it shares the resistance.
Option D: Option D is incorrect: letermovir is for prophylaxis in low-replication settings and selects rapidly for resistance when used against active replication; it is not the treatment for established ganciclovir-resistant disease.
Option E: Option E is incorrect: CMV lacks the thymidine kinase that activates acyclovir, so acyclovir is not effective anti-CMV therapy. UL54 mutations, by contrast, can produce cross-resistance across ganciclovir, foscarnet, and cidofovir.
17. Progressive multifocal leukoencephalopathy (PML) is a demyelinating brain disease caused by JC virus infection of oligodendrocytes (the myelin-producing cells) in patients with profound T-cell deficiency. Cidofovir and other antivirals have failed to show benefit. Drawing on the same principle that governs PTLD and BK nephropathy management, what is the primary therapeutic strategy in PML?
A) Lifelong suppressive foscarnet to control JC virus replication
B) High-dose IV ganciclovir, since JC virus is a polyomavirus like BK
C) Restoration of JC virus-specific T-cell immunity — for example, starting or optimizing antiretroviral therapy in HIV, or withdrawing the offending immunosuppressant
D) Letermovir, because polyomaviruses share the terminase target
E) Intrathecal cidofovir, which concentrates the drug at the site of disease
ANSWER: C
Rationale:
This bridges the recurring theme — when no effective antiviral exists, restore immune control — to a new pathogen. Option C is correct: no antiviral has proven efficacy against JC virus, so management centers on rebuilding JCV-specific cytotoxic T-cell surveillance; in HIV-associated PML this means immediate antiretroviral therapy to recover CD4 counts, and in drug-associated PML (for example, natalizumab) it means stopping the offending agent.
Option A: Option A is incorrect: foscarnet is not effective against JC virus.
Option B: Option B is incorrect: although JC virus is a polyomavirus, ganciclovir is not active against it, and "same family as BK" does not confer susceptibility — note BK itself also has no effective approved antiviral.
Option D: Option D is incorrect: the terminase target is specific to CMV, not polyomaviruses.
Option E: Option E is incorrect: cidofovir (by any route) failed to show benefit in PML. The unifying principle across PTLD, BK nephropathy, and PML is that immune reconstitution, not direct antiviral therapy, drives control.
18. Natalizumab, a monoclonal antibody used in multiple sclerosis, is associated with PML even though the patient is not otherwise immunosuppressed in the usual transplant sense. Based on its mechanism, why does natalizumab raise PML risk?
A) It depletes circulating B cells, the reservoir of JC virus
B) It blocks the alpha-4 integrin (VLA-4) that lymphocytes use to cross from blood into the central nervous system, so JC virus-specific T cells can no longer patrol the brain
C) It directly reactivates latent JC virus in oligodendrocytes
D) It inhibits the viral DNA polymerase, paradoxically promoting resistant JC virus
E) It suppresses the bone marrow, causing global lymphopenia
ANSWER: B
Rationale:
This bridges the immune-surveillance theme into a drug-specific mechanism of localized immune failure. Option B is correct: natalizumab is an anti-alpha-4 integrin antibody that blocks VLA-4 binding to VCAM-1, preventing lymphocytes from trafficking out of the blood into tissues including the CNS; this dampens the harmful CNS inflammation of multiple sclerosis but simultaneously removes JC virus-specific cytotoxic T-cell surveillance of the brain, allowing PML to develop.
Option A: Option A is incorrect: B-cell depletion describes rituximab, not natalizumab, and PML control is a T-cell phenomenon.
Option C: Option C is incorrect: natalizumab does not directly reactivate the virus; it removes the immune patrol that keeps it in check.
Option D: Option D is incorrect: natalizumab is not a polymerase inhibitor.
Option E: Option E is incorrect: it does not cause marrow suppression or global lymphopenia — circulating lymphocyte counts may even rise as cells are blocked from entering tissue. PML risk with natalizumab is stratified by JC virus antibody index, treatment duration beyond 24 months, and prior immunosuppressant use.
19. An asymptomatic transplant recipient has a persistently very high plasma HHV-6 (human herpesvirus 6) viral load — over a million copies per milliliter — that does not change with antiviral therapy and is present in every sample. The clinical picture does not fit active HHV-6 disease. What phenomenon best explains this finding, and how is it confirmed?
A) Letermovir-resistant HHV-6, confirmed by UL56 genotyping
B) Active HHV-6 encephalitis, confirmed by brain biopsy
C) A laboratory contamination artifact, confirmed by simply repeating the plasma PCR
D) Inherited chromosomally integrated HHV-6 (iciHHV-6), in which the viral genome is integrated into the patient's chromosomes in every cell; confirmed by detecting HHV-6 DNA in hair follicle cells
E) Reactivation of latent CMV cross-reacting on the HHV-6 assay, confirmed by CMV PCR
ANSWER: D
Rationale:
This bridges the concept that PCR results require interpretation (introduced for CMV in Question 10) to a different and opposite pitfall — a falsely HIGH result. Option D is correct: inherited chromosomally integrated HHV-6 (iciHHV-6) occurs in roughly 1% of people; because the viral genome is integrated into host chromosomes, every nucleated cell carries it, producing constitutively very high, treatment-unresponsive plasma DNA levels that mimic active replication. It is confirmed by finding HHV-6 DNA in hair follicle cells (host cells that carry the integrated genome), distinguishing it from true viremia.
Option A: Option A is incorrect: a static, treatment-independent level over a million copies is not the signature of drug resistance, and HHV-6 prophylaxis/letermovir framing does not apply.
Option B: Option B is incorrect: HHV-6 encephalitis is a clinical CNS syndrome diagnosed by CSF PCR, and this patient is asymptomatic.
Option C: Option C is incorrect: a reproducible result across samples is not contamination, and repeating plasma PCR cannot distinguish integration from viremia.
Option E: Option E is incorrect: the assay is HHV-6-specific and CMV does not cross-react in this way. Recognizing iciHHV-6 prevents unnecessary antiviral treatment of a healthy carrier state.
20. Maribavir is an oral agent for CMV infection that is refractory to standard drugs. Interestingly, it acts on the same CMV enzyme (UL97) that ganciclovir depends on for its activation, yet maribavir retains activity against most ganciclovir-resistant UL97 mutants. Which statement correctly explains the relationship between the two drugs and UL97?
A) Maribavir is phosphorylated by UL97 in the same way ganciclovir is, so the two are fully cross-resistant
B) Maribavir inhibits the viral DNA polymerase and only incidentally affects UL97
C) Maribavir works by inhibiting the terminase, unrelated to UL97
D) Maribavir requires UL97 to activate it, just as ganciclovir does, so UL97 mutations abolish both
E) Maribavir directly inhibits the UL97 kinase at a binding site distinct from the residues where ganciclovir-activating mutations occur, so it blocks the enzyme rather than needing it for activation
ANSWER: E
Rationale:
This bridges the UL97 activation concept (Questions 3 and 16) to a drug that uses the same enzyme in the opposite way. Option E is correct: ganciclovir NEEDS UL97 to phosphorylate (activate) it, whereas maribavir INHIBITS the UL97 kinase directly; because maribavir binds at a site distinct from the codons where the common ganciclovir-resistance mutations arise, it remains active against most UL97-mutant, ganciclovir-resistant strains.
Option A: Option A is incorrect: maribavir is not a UL97 substrate and is not broadly cross-resistant with ganciclovir.
Option B: Option B is incorrect: maribavir's primary target is the UL97 kinase, not the DNA polymerase.
Option C: Option C is incorrect: terminase inhibition is letermovir's mechanism.
Option D: Option D is incorrect: this reverses the relationship — maribavir does not depend on UL97 for activation. A practical consequence is that maribavir and ganciclovir should not be co-administered, since maribavir's inhibition of UL97 would impair ganciclovir activation.
21. Recall that cidofovir's nephrotoxicity arises from its uptake into proximal tubular cells by the organic anion transporter OAT1. Brincidofovir is a lipid-conjugate prodrug of cidofovir designed to avoid this toxicity. Based on that design, how does brincidofovir escape the nephrotoxicity that limits cidofovir?
A) Its lipid conjugate lets it enter cells through lipid (membrane) endocytosis rather than via OAT1, so it bypasses the proximal tubular uptake that drives cidofovir nephrotoxicity
B) It is renally inert because it is not a nucleotide analogue at all
C) It is co-formulated with probenecid, making separate OAT1 blockade unnecessary
D) It is activated only by viral kinases, so it never accumulates in renal cells
E) It is cleared entirely by the liver and never reaches the kidney in any form
ANSWER: A
Rationale:
This bridges the OAT1/cidofovir toxicity mechanism (Question 15) to the rational drug design of a successor agent. Option A is correct: brincidofovir attaches a lipid group to cidofovir so the molecule enters cells through lipid-mediated endocytosis rather than OAT1-mediated tubular uptake; intracellular phospholipases then release active cidofovir diphosphate. Avoiding OAT1 uptake spares the proximal tubule, achieving high intracellular drug levels without the characteristic nephrotoxicity.
Option B: Option B is incorrect: brincidofovir delivers the same active cidofovir species intracellularly — it is very much a nucleotide-analogue prodrug.
Option C: Option C is incorrect: it is not a probenecid co-formulation; the protection is structural, not from competitive OAT1 blockade.
Option D: Option D is incorrect: cidofovir-class drugs are activated by HOST, not viral, kinases — that is precisely why they cover kinase-independent resistance.
Option E: Option E is incorrect: the key is the route of cellular entry, not exclusive hepatic clearance. Despite this favorable renal profile, a phase 3 adenovirus trial did not show a survival benefit, attributed in part to brincidofovir's own immunosuppressive effect at the doses studied.
22. Throughout this module, restoring immune function has been the goal of management. But immune recovery can itself cause harm. A patient with HIV and treated CMV retinitis has an excellent virologic response after starting antiretroviral therapy, yet the retinitis paradoxically worsens with new intraocular inflammation as the CD4 count rises. What does this illustrate?
A) Antiviral drug resistance emerging during therapy
B) A new, unrelated opportunistic infection
C) Immune reconstitution inflammatory syndrome (IRIS) — a paradoxical inflammatory worsening of an existing infection as recovering immune cells mount a response against residual antigen
D) Direct retinal toxicity of the antiretroviral regimen
E) Simple treatment failure requiring a different anti-CMV agent
ANSWER: C
Rationale:
This final bridge question ties the module's unifying theme to its principal hazard. Option C is correct: immune reconstitution inflammatory syndrome (IRIS) is a paradoxical worsening of an existing or subclinical infection driven by the returning immune response — here, recovering CD4+ T cells mounting inflammation against residual CMV antigen despite good virologic control; CMV IRIS classically presents as worsening retinitis or uveitis and may require careful coordination of CMV treatment, antiretroviral therapy, and sometimes short-course corticosteroids to control inflammation without abrogating immune recovery.
Option A: Option A is incorrect: the virologic response is excellent, arguing against resistance.
Option B: Option B is incorrect: the worsening is of the SAME, already-known infection, not a new one.
Option D: Option D is incorrect: this pattern reflects immune-mediated inflammation, not direct drug toxicity to the retina.
Option E: Option E is incorrect: treatment failure would show rising viral load, not improvement with paradoxical inflammation. The same principle explains why reducing immunosuppression in transplant recipients can unmask previously subclinical EBV, adenovirus, or HHV-6 infection.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.